Individualising type 2 diabetes management: new treatment options and models of care

N Wah Cheung
Med J Aust 2012; 197 (4): . || doi: 10.5694/mja12.11041
Published online: 20 August 2012

Better outcomes require tailored strategies

The past 15 years has seen the advent of many new classes of antidiabetic agents. We now have biguanides, sulfonylureas, thiazolidinediones, dipeptidyl-peptidase IV inhibitors, glucagon-like peptide 1 receptor agonists, a variety of insulins and α-glucosidase inhibitors. This has resulted in a surfeit of choice, but has also increased the complexity of decision making as there is no simple algorithm for escalation of treatment that is optimal for all patients.

  • N Wah Cheung

  • Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, NSW.


Competing interests:

I am the President of the Australian Diabetes Society and a member of the Australian Government’s Diabetes Advisory Group for the Diabetes Care Project.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.